The protection observed with the anastrazole treatment of the previous study was corroborated by a study with metformin treatment which reversed PAH and decreased pulmonary vascular remodeling via aromatase inhibition [93]. This evidence concerns the gene CYP19A1 and pulmonary arterial hypertension.